Esperion Therapeutics Inc (ESPR)
2.16
-0.13
(-5.68%)
USD |
NASDAQ |
May 31, 16:00
2.16
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics Cash from Financing (TTM): 91.57M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 91.57M |
December 31, 2023 | 50.46M |
September 30, 2023 | 15.63M |
June 30, 2023 | 66.24M |
March 31, 2023 | 83.53M |
December 31, 2022 | 32.61M |
September 30, 2022 | 276.37M |
June 30, 2022 | 233.74M |
March 31, 2022 | 264.74M |
December 31, 2021 | 268.22M |
September 30, 2021 | 225.25M |
June 30, 2021 | 223.20M |
March 31, 2021 | 177.76M |
December 31, 2020 | 201.72M |
September 30, 2020 | 38.30M |
June 30, 2020 | 37.68M |
March 31, 2020 | 160.54M |
December 31, 2019 | 136.20M |
September 30, 2019 | 129.52M |
June 30, 2019 | 128.42M |
March 31, 2019 | 3.07M |
December 31, 2018 | 10.69M |
September 30, 2018 | 10.27M |
Date | Value |
---|---|
June 30, 2018 | 174.46M |
March 31, 2018 | 172.90M |
December 31, 2017 | 163.46M |
September 30, 2017 | 163.13M |
June 30, 2017 | -1.324M |
March 31, 2017 | -1.345M |
December 31, 2016 | -1.559M |
September 30, 2016 | -1.532M |
June 30, 2016 | -1.012M |
March 31, 2016 | -0.256M |
December 31, 2015 | 190.52M |
September 30, 2015 | 282.80M |
June 30, 2015 | 282.81M |
March 31, 2015 | 287.48M |
December 31, 2014 | 97.12M |
September 30, 2014 | 5.049M |
June 30, 2014 | 78.35M |
March 31, 2014 | 89.19M |
December 31, 2013 | 89.14M |
September 30, 2013 | 95.03M |
June 30, 2013 | 25.62M |
March 31, 2013 | 9.751M |
December 31, 2012 | 15.75M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
15.63M
Minimum
Sep 2023
276.37M
Maximum
Sep 2022
142.09M
Average
132.86M
Median
Cash from Financing (TTM) Benchmarks
Dynavax Technologies Corp | 0.273M |
Masimo Corp | -48.40M |
United Therapeutics Corp | -1.128B |
Deciphera Pharmaceuticals Inc | 17.84M |
Ligand Pharmaceuticals Inc | -46.99M |